<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04122456</url>
  </required_header>
  <id_info>
    <org_study_id>06753</org_study_id>
    <nct_id>NCT04122456</nct_id>
  </id_info>
  <brief_title>DNA Repair Activity in the Skin of Day and Night Shift Workers</brief_title>
  <official_title>Pilot Study on DNA Repair Activity in the Skin of Day and Night Shift Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey B. Travers, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wright State Physicians</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test how the skin of night shift workers responds to&#xD;
      artificial sunlight (ultraviolet B radiation; UVB) at two different times of the day in&#xD;
      comparison to normal day shift workers. After the skin biopsies are obtained, they will be&#xD;
      brought to the laboratory to be exposed to UVB radiation and to measure UVB responses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expression level of the DNA repair factor XPA at two times of the day in the skin of day and night shift workers.</measure>
    <time_frame>After 1 hour incubation from ultraviolet B radiation exposure.</time_frame>
    <description>Reverse transcription quantitative PCR (RT-qPCR) and immunohistochemistry will be used to measure XPA expression at the mRNA and protein level, respectively, in skin samples obtained at 8 am and 4 pm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression levels of core clock genes at two times of the day in the skin of day and night shift works.</measure>
    <time_frame>After 1 hour incubation from ultraviolet B radiation exposure.</time_frame>
    <description>Reverse Transcription Quantitative PCR (RT-qPCR) is used to measure the core circadian clock gene expression at the mRNA level in the skin samples obtained at 8 AM and 4 PM.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of the nucleotide excision repair (NER) system at two times of the day in day and night shift workers.</measure>
    <time_frame>After 1 hour incubation from ultraviolet B radiation exposure.</time_frame>
    <description>A biochemical assay of nucleotide excision repair is used to measure NER in the skin samples obtained at 8 AM and 4 PM.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activation of DNA damage kinase signaling pathways at two times of the day in the skin of day and night shift workers.</measure>
    <time_frame>After 1 hour incubation from ultraviolet B radiation exposure.</time_frame>
    <description>Immunohistochemistry is used to measure DNA damage kinase signaling (phosphorylated Chk1 and p53) in the skin samples obtained at 8 AM and 4 PM.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Day Shift Work Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Night Shift Work Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Night shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Ultraviolet B Radiation</intervention_name>
    <description>One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.</description>
    <arm_group_label>Day Shift Work Schedule</arm_group_label>
    <arm_group_label>Night Shift Work Schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Ultraviolet B Radiation</intervention_name>
    <description>One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.</description>
    <arm_group_label>Day Shift Work Schedule</arm_group_label>
    <arm_group_label>Night Shift Work Schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/Female&#xD;
&#xD;
          -  Fair skin (Fitzpatrick types I and II)&#xD;
&#xD;
          -  Age 18 to 40&#xD;
&#xD;
          -  Able to comprehend procedures/risks&#xD;
&#xD;
          -  Primarily work and are awake during normal daylight hours (6 am to 6 pm), or primarily&#xD;
             work and are awake during night shifts hours (between the hours of 6 pm and 6 am) or&#xD;
             may work a mixture of these shifts over the past 3 months. Rotating shifts will be&#xD;
             categorized based on the majority of hours worked on average during the last 3 months.&#xD;
             Able to fill out a 3-month calendar of work schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known photosensitivity&#xD;
&#xD;
          -  Currently on photosensitizing medications&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  On any hormonal agents (e.g., birth control pills)&#xD;
&#xD;
          -  History of abnormal scarring&#xD;
&#xD;
          -  History of skin infections&#xD;
&#xD;
          -  History of skin cancers&#xD;
&#xD;
          -  History of sleep disorders such as sleep apnea or insomnia&#xD;
&#xD;
          -  Known allergy to lidocaine local anesthetic&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Other serious health issues&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Travers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wright State Physicians Pharmacology Translational Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manager, Clinical Research Operations</last_name>
    <phone>937-245-7500</phone>
    <email>pturesearch@wrightstatephysicians.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regulatory Specialist</last_name>
    <phone>937-245-7500</phone>
    <email>pturesearch@wrightstatephysicians.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wright State Physicians</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Pharmacology Translational Unit</last_name>
      <phone>937-245-7500</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wright State Physicians</investigator_affiliation>
    <investigator_full_name>Jeffrey B. Travers, MD, PhD</investigator_full_name>
    <investigator_title>Chair of Department of Pharmacology and Toxicology and Professor of Dermatology for Boonshoft School of Medicine at Wright State University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

